MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 129 filers reported holding MERSANA THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 297.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,155 | -64.9% | 10,358 | -9.0% | 0.01% | -63.6% |
| Q2 2023 | $37,460 | -35.7% | 11,386 | -19.7% | 0.02% | -31.2% |
| Q1 2023 | $58,247 | -49.3% | 14,172 | -27.8% | 0.03% | -46.7% |
| Q4 2022 | $114,961 | -51.5% | 19,618 | -44.0% | 0.06% | -36.2% |
| Q3 2022 | $237,000 | +47.2% | 35,048 | +0.7% | 0.09% | +56.7% |
| Q2 2022 | $161,000 | +42.5% | 34,799 | +23.0% | 0.06% | +17.6% |
| Q1 2022 | $113,000 | -39.2% | 28,294 | -5.6% | 0.05% | -27.1% |
| Q4 2021 | $186,000 | +38.8% | 29,974 | +111.6% | 0.07% | +18.6% |
| Q3 2021 | $134,000 | -34.0% | 14,165 | -5.0% | 0.06% | -28.9% |
| Q2 2021 | $203,000 | +6.8% | 14,912 | +26.7% | 0.08% | +3.8% |
| Q1 2021 | $190,000 | -38.3% | 11,771 | +1.8% | 0.08% | -37.5% |
| Q4 2020 | $308,000 | +6.9% | 11,560 | -25.2% | 0.13% | -15.2% |
| Q3 2020 | $288,000 | -29.9% | 15,464 | -12.0% | 0.15% | -22.6% |
| Q2 2020 | $411,000 | – | 17,574 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 4,005,600 | $64,810,000 | 6.21% |
| Bain Capital Life Sciences Investors, LLC | 3,695,667 | $59,796,000 | 3.39% |
| COMMODORE CAPITAL LP | 429,228 | $6,945,000 | 2.77% |
| ACUTA CAPITAL PARTNERS, LLC | 357,689 | $5,787,000 | 2.09% |
| Avoro Capital Advisors LLC | 6,800,000 | $110,024,000 | 1.90% |
| Ghost Tree Capital, LLC | 450,000 | $7,281,000 | 1.71% |
| RHO CAPITAL PARTNERS INC | 796,458 | $12,887,000 | 1.24% |
| Rock Springs Capital Management LP | 2,775,127 | $44,902,000 | 0.98% |
| Sio Capital Management, LLC | 157,259 | $2,544,000 | 0.52% |
| Bellevue Group AG | 2,850,010 | $46,113,000 | 0.49% |